Vimarsana
Biggest News Aggregation in the World

Page 5 - Plight Chain News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Plight Chain. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Plight Chain Today - Breaking & Trending Today

New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pretreated Patients with Multiple Myeloma - Vimarsana News

New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pretreated Patients with Multiple Myeloma

Published: December 14, 2021

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced the first presentation of Phase 2 data and updated Phase 1 data from the...

Source: prnewswire.com
Related Topics:
United StatesYusri ElsayedObrian KenneyPhilippe MoreauJessica MooreJanssen Biotech IncAmerican Society Of Hematology Annual MeetingCancer Research InstituteJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonAmerican Society Of HematologyUniversity HospitalAmerican Cancer SocietyNone Of The Janssen Pharmaceutical CompaniesOther Administration ReactionsDrug AdministrationEuropean CommissionAmerican Cancer Society Facts StatisticsExchange CommissionCompanies Of JohnsonAmgen IncEuropean Medicines AgencyAmerican SocietyConfidence Interval
New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pretreated Patients with Multiple Myeloma - Vimarsana News

New Data from MajesTEC-1 Study Show Continued Deep and Durable Responses of Teclistamab (BCMAxCD3 Bispecific Antibody) in Treatment of Heavily Pretreated Patients with Multiple Myeloma

Published: December 13, 2021

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced the first presentation of Phase 2 data and updated Phase 1 data from the...

Source: prnewswire.com
Related Topics:
United StatesYusri ElsayedObrian KenneyPhilippe MoreauJessica MooreJanssen Biotech IncAmerican Society Of Hematology Annual MeetingCancer Research InstituteJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonAmerican Society Of HematologyUniversity HospitalAmerican Cancer SocietyNone Of The Janssen Pharmaceutical CompaniesOther Administration ReactionsDrug AdministrationEuropean CommissionAmerican Cancer Society Facts StatisticsExchange CommissionCompanies Of JohnsonAmgen IncEuropean Medicines AgencyAmerican SocietyConfidence Interval
Janssen Presents Updated Results Evaluating First-in-Class Talquetamab (GPRC5DxCD3 Bispecific Antibody) in Heavily Pretreated Patients with Multiple Myeloma - Vimarsana News

Janssen Presents Updated Results Evaluating First-in-Class Talquetamab (GPRC5DxCD3 Bispecific Antibody) in Heavily Pretreated Patients with Multiple Myeloma

Published: December 11, 2021

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the MonumenTAL-1 Phase 1 first-in-human...

Source: prnewswire.com
Related Topics:
United StatesNamita KrishnanObrian KenneySen ZhuangJessica MooreJanssen Biotech IncAmerican Society Of Hematology Annual MeetingJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonAmerican Society Of HematologyReceptor Familyc GroupClinical ResearchDepartment Of HematologyAmerican Cancer SocietyNone Of The Janssen Pharmaceutical CompaniesOther Administration ReactionsEuropean CommissionDivision Of Multiple MyelomaExchange CommissionCompanies Of JohnsonAmgen IncCity Of Hope Comprehensive Cancer CenterAmerican SocietyMultiple Myeloma
Janssen Presents Updated Results Evaluating First-in-Class Talquetamab (GPRC5DxCD3 Bispecific Antibody) in Heavily Pretreated Patients with Multiple Myeloma - Vimarsana News

Janssen Presents Updated Results Evaluating First-in-Class Talquetamab (GPRC5DxCD3 Bispecific Antibody) in Heavily Pretreated Patients with Multiple Myeloma

Published: December 11, 2021

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today updated results from the MonumenTAL-1 Phase 1 first-in-human...

Source: prnewswire.com
Related Topics:
United StatesNamita KrishnanObrian KenneySen ZhuangJessica MooreJanssen Biotech IncAmerican Society Of Hematology Annual MeetingJanssen Research DevelopmentJanssen Pharmaceutical CompaniesJanssen Pharmaceutical Companies Of JohnsonAmerican Society Of HematologyReceptor Familyc GroupClinical ResearchDepartment Of HematologyAmerican Cancer SocietyNone Of The Janssen Pharmaceutical CompaniesOther Administration ReactionsEuropean CommissionDivision Of Multiple MyelomaExchange CommissionCompanies Of JohnsonAmgen IncCity Of Hope Comprehensive Cancer CenterAmerican SocietyMultiple Myeloma
What does the future hold for Light-chain Amyloidosis? - Vimarsana News

What does the future hold for Light-chain Amyloidosis?

Published: December 1, 2021

- PMLiVE

Source: pmlive.com
Related Topics:
United StatesUnited KingdomAstrazeneca AlexionSanofi IsatuximabThomas NuryHarrison GaigerEuropean Haematology AssociationAmerican Society Of Clinical OncologyOur Quantitative Centre Of ExcellenceResearch PartnershipPlight ChainResearch ManagerMultiple MyelomaClinical OncologyAnnual MeetingQuantitative Centre